LML is delighted to announce three new appointments to the International Collaborative Bioscience Innovation & Law (Inter-CeBIL) Programme, funded by the Novo Nordisk Foundation.
Professor Michael Hopkins joins LML as a Senior Research Associate (part-time). Michael has over 25 years’ experience studying the sociotechnical challenges associated with medical innovation. He has led international research projects that explore policy issues related to diverse aspects of pharmaceuticals, diagnostics, and emerging health technologies.
In recent years Michael has advised the UK Prime Minister’s Council on Science and Technology, and consulted for a wide range of organisations seeking to develop policy relating to medical innovation, including the World Health Organisation and the UK Department of Health and Social Care.
Michael initially trained as a Biologist, before taking an MSc (with distinction) in Technology and Innovation management, and a DPhil in Science and Technology Policy at the University of Sussex’s Science Policy Research Unit (SPRU). He will work with us on a 0.2 full-time equivalent basis while continuing as Professor of Innovation Management at the University of Sussex Business School.
“I’m delighted to be working once again with colleagues at LML with whom I have had a long and productive collaboration addressing complex global challenges in medical innovation and governance”, Michael said.
Laurence Childs joins as a part-time Research Assistant, bringing substantial experience from the pharmaceutical and health policy sectors.
In his previous role as Account Manager with MHP Group’s Health team, Laurence worked across national and international policy, campaign strategy, and communications in areas including UK respiratory prescribing, value assessment standards for innovative oncology medicines, and EU orphan drug regulation.
His other previous roles span health economic data analysis, market access policy and consultancy for rare disease and oncology markets, including roles at Dolon, Triangulate Health, and the United Nations Office on Drugs and Crime. He holds an MSc in International Health Policy from LSE and a BA in Politics and Sociology from University College Dublin. His understanding of pharma regulation, market access, and health innovation will be a valuable asset to Inter-CeBIL’s research.
“Having worked in both the private and policy sides of the health sector, I’m looking forward to bringing a practical perspective to LML’s research on regulation and innovation”, Laurence said.
Natalie Kiilu takes up the role of Research Projects Coordinator and Research Assistant, replacing Jake Widjaya, who is headed to London as a Lord Denning Scholar to complete his Bar Training Course at the Inns of Court College of Advocacy.
Natalie recently completed the Cambridge LLM with strong results, specialising in intellectual property and health law. Originally from Kenya, she has a particular interest in pharmaceutical innovation and access to medicines in sub-Saharan Africa. Her academic expertise, combined with her international perspective, will make a significant contribution to Inter-CeBIL’s global research goals.
“I’m thrilled to join LML and help advance research that has real potential to improve access to medicines in regions where it’s most needed”, Natalie said.
We warmly welcome Michael, Laurence and Natalie to the LML/Inter-CeBIL team and look forward to working together.
Inter-CeBIL is a multi-institutional research collaboration between the universities of Copenhagen, Cambridge and Harvard that brings together experts in law, ethics, and the life sciences to address pressing challenges in health innovation, regulation, and access to medicines.